Aspects of the disclosure relate to methods and compositions for treatment of certain ocular diseases and disorders, for example age-related macular degeneration (AMD). In some embodiments, the methods comprise administering a subject having AMD one or more therapeutic agents that modulate the mTORCl pathway (or a component thereof). The disclosure is based, in part, on methods for treating AMD in a subject by administering one or more kinase inhibitors, for example one or more serine/threonine kinase inhibitors. In some embodiments, at least one of the serine/threonine kinase inhibitors is a Ribosomal protein S6 kinase beta-1 (S6K1) inhibitor.

Methods and compositions comprising free fatty acids for the treatment, including prevention, of viral infections, including the treatment of Acute Respiratory Distress Syndrome (ARDS)/. The compositions comprising free fatty acids, optionally linolenic acid, linoleic acid, and/or palmitic acid, may be used in methods for treating viral infections, optionally, coronavirus infections, for example, SARS-CoV, MERS-CoV, and/or SARS-CoV-2/COVID-19, and influenza virus infections, optionally, H1N1 and/or H5N1.

Methods and compositions comprising free fatty acids for the treatment, including prevention, of viral infections, including the treatment of Acute Respiratory Distress Syndrome (ARDS)/. The compositions comprising free fatty acids, optionally linolenic acid, linoleic acid, and/or palmitic acid, may be used in methods for treating viral infections, optionally, coronavirus infections, for example, SARS-CoV, MERS-CoV, and/or SARS-CoV-2/COVID-19, and influenza virus infections, optionally, H1N1 and/or H5N1.

A fatty acid based composition for treatment and/or prevention of enveloped-virus related infections by administering fatty acid based compositions. The present invention further provides a free fatty acid based sprayable composition to prevent and/or treatment of SARS-Virus related infections. The fatty acids used in the present invention are Linoleic acid (LA), α-linolenic acid (ALA) and gamma-linolenic acid (GLA). In a preferred embodiment, we propose that topical administration of naturally occurring fatty acids in an optimal formulation may be beneficial in the prophylaxis of respiratory enveloped viruses and in particular the lipid-rich SARS-CoV-2 virus. This could be administered via nasal and/or oral route. The composition comprises at least one fatty acid, a suitable carrier, preservative, cosolvents and surfactants and/or cyclodextrin used as an excipient that may also enhance anti-viral properties.

A fatty acid based composition for treatment and/or prevention of enveloped-virus related infections by administering fatty acid based compositions. The present invention further provides a free fatty acid based sprayable composition to prevent and/or treatment of SARS-Virus related infections. The fatty acids used in the present invention are Linoleic acid (LA), α-linolenic acid (ALA) and gamma-linolenic acid (GLA). In a preferred embodiment, we propose that topical administration of naturally occurring fatty acids in an optimal formulation may be beneficial in the prophylaxis of respiratory enveloped viruses and in particular the lipid-rich SARS-CoV-2 virus. This could be administered via nasal and/or oral route. The composition comprises at least one fatty acid, a suitable carrier, preservative, cosolvents and surfactants and/or cyclodextrin used as an excipient that may also enhance anti-viral properties.

A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

The present invention relates to nutritional supplements for the human diet used to manipulate HDL cholesterol, LDL cholesterol, and triglyceride levels in human blood plasma. The invention contains a novel combination of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) present in Fish Oil, alpha-linolenic acid (ALA) present in Flaxseed Oil, Vitamin E in the form of d-alpha-tocopherol, Allicin present in Garlic, Phosphatidylcholine present in Lecithin, plant phytochemicals present in Parsley herb, citrus flavonoids present in Lemon fruit and Rutin (from Sophora japonica), and Capsaicin present in Cayenne Pepper.

The present invention relates to nutritional supplements for the human diet used to manipulate HDL cholesterol, LDL cholesterol, and triglyceride levels in human blood plasma. The invention contains a novel combination of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) present in Fish Oil, alpha-linolenic acid (ALA) present in Flaxseed Oil, Vitamin E in the form of d-alpha-tocopherol, Allicin present in Garlic, Phosphatidylcholine present in Lecithin, plant phytochemicals present in Parsley herb, citrus flavonoids present in Lemon fruit and Rutin (from Sophora japonica), and Capsaicin present in Cayenne Pepper.

The present application is concerned with methods for increasing the bioavailability and/or activity of agents and in particular allows selective targeting of an agent to, or via, the liver or allows the liver to be bypassed. By selecting which of saturated fatty acids (SFA), short chain fatty acids (SCFA), medium chain fatty acids (MCFA), polyunsaturated fatty acids (PUFA), monounsaturated fatty acids (MUFAs) and long chain fatty acids (LCFA) are present in a composition and which predominates it is possible to substantially boost bioavailability and also to selectively target whether an agent is delivered to, or via, the liver or alternatively bypasses the liver. The approach is a versatile platform technology which may be applied to agents in general helping achieve better and more efficient delivery. In one preferred embodiment particular carotenoids are employed to further influence whether delivery is to, or via, the liver, or bypasses the liver.